-
11:59:04 AM

NRBO Stock News

09/15/23 8:01 AM
Nasdaq : NRBO
clinical trial
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
"Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a...
RHEA-AI
neutral
08/03/23 8:01 AM
Nasdaq : NRBO
clinical trial
NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has received the first site Institutional Review Board approval for Zeid Kayali, M.D., Medical Director at Inland Empire Liver Foundation, in Rialto, CA, to proceed with the Phase 2 a...
RHEA-AI
neutral
06/13/23 8:01 AM
Nasdaq : NRBO
NeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific Sessions
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that data on DA-1726, a novel oxyntomodulin analogue functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, was accepted for one ePoster theater...
RHEA-AI
neutral